WHO 2/3级胶质瘤分子分型与切除程度的基因组预后因素:单中心九年数据
单中心回顾9年209例WHO 2级与3级胶质瘤(157例IDH1/2突变、52例IDH野生型),分析IDH状态、EGFR扩增等分子标志与切除程度同生存的关系。结果显示IDH1/2突变与更长OS和PFS相关,但不影响恶性进展时间;无EGFR扩增、较年轻和切除程度≥80%为独立有利OS因素。
要点
- IDH1/2突变者OS与PFS更长,但恶性进展时间无差异。
- 无EGFR扩增、较年轻、EOR≥80%为独立有利OS因素。
- IDH野生型中年龄较大与EOR<80%与更差OS相关。
核心结论
- IDH1/2突变带来更长OS和PFS,但不能防止恶性进展。
- 无EGFR扩增、较年轻和更大EOR是有利OS预后因素。
- IDH野生型队列中年龄较大和EOR较小与更差OS相关。
研究设计与样本
- 单中心 retrospective 回顾性研究,覆盖2010-2019年共9年。
- 纳入分子分层的WHO 2级和3级胶质瘤,2级167例、3级42例,共209例。
- 其中IDH1/2突变157例,IDH野生型52例。
- 记录临床数据、IDH1/IDH2状态、EGFR扩增及其他分子标志。
- 结局指标为PFS、OS和恶性进展时间(TtMP)。
主要发现
- IDH1/2突变与更长OS相关(P < 0.0001)和更长PFS相关(P < 0.0001)。
- IDH1/2突变与TtMP无显著相关(P = 0.314)。
- 无EGFR扩增、较年轻和EOR≥80%被确定为独立有利OS预后因素。
- IDH野生型队列多因素分析中,年龄较大(P = 0.003)和EOR<80%(P = 0.007)与更差OS相关。
- IDH野生型队列中EGFR扩增显示OS缩短趋势(P = 0.073)。
关键数值与推荐
- IDH1/2突变:OS P < 0.0001,PFS P < 0.0001,TtMP P = 0.314。
- EOR≥80%为独立有利OS预后因素。
- IDH野生型:年龄较大P = 0.003、EOR<80% P = 0.007与更差OS相关。
- IDH野生型:EGFR扩增与更短OS呈趋势(P = 0.073)。
临床怎么用
- 对WHO 2/3级胶质瘤应结合IDH状态与EGFR扩增等分子标志进行预后分层。
- IDH野生型患者中应重视年龄与切除程度对OS的影响。
- 争取EOR≥80%可能有助于改善OS。
局限性
- 单中心回顾性设计,证据级别受限。
- 样本量有限(共209例,IDH野生型52例)。
- EGFR扩增在IDH野生型中仅为趋势性结果(P = 0.073)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: World Health Organization (WHO) grade II and III isocitrate dehydrogenase wild-type (IDH-wt) gliomas are often treated as WHO grade IV glioblastomas. However, cumulative evidence indicates that IDH mutation status alone is insufficient in predicting survival. The current study examines molecular and clinical markers to further prognostically stratify WHO grade II and III gliomas, in particular, IDH-wt. METHODS: A single institution's records were retrospectively reviewed for molecularly stratified WHO grade II and grade III gliomas over a 9-year period (2010-2019). Clinical data, IDH1/IDH2 status, EGFR amplification, and other molecular markers were recorded and correlated to the study outcomes. These outcomes were defined as progression-free survival (PFS), overall survival (OS), and time to malignant progression (TtMP). RESULTS: A total of 167 and 42 WHO grade II and III gliomas, respectively, were identified, totaling 209 cases with 157 IDH1/2 mutated and 52 IDH-wt tumors. The presence of IDH1/2 mutation was associated with longer OS (P < 0.0001) and PFS (P < 0.0001) but not with TtMP (P = 0.314). Lack of EGFR amplification, younger age, and greater extent of resection (EOR) (≥80%) were identified as independent, favorable OS prognostic factors. In the IDH-wt cohort, multivariate analysis indicated that older age (P = 0.003) and lesser EOR (<80%) (P = 0.007) are associated with worse OS. In addition, EGFR amplification showed a trend toward shorter OS in the IDH-wt cohort (P = 0.073). CONCLUSIONS: IDH1/2 mutation favors longer OS and PFS but does not protect from malignant progression. Lack of EGFR amplification, younger age and greater EOR are favorable OS prognosticators. In the IDH-wt cohort, older age and lesser EOR were linked to worse OS.
引用
- Lasica AB, Jaunmuktane Z, Fersht N, et al. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data. World Neurosurg. 2021. PMID: 33866029. doi:10.1016/j.wneu.2021.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。